

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 May 2020 (28.05.2020)



(10) International Publication Number
WO 2020/106886 A1

- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *C07K 16/18* (2006.01)
- (21) **International Application Number:**
PCT/US2019/062479
- (22) **International Filing Date:**
20 November 2019 (20.11.2019)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/769,989 20 November 2018 (20.11.2018) US
62/788,700 04 January 2019 (04.01.2019) US
62/792,835 15 January 2019 (15.01.2019) US
- (71) **Applicant:** CORNELL UNIVERSITY [US/US]; Center for Technology Licensing, 395 Pine Tree Road, Suite 310, Ithaca, New York 14850 (US).
- (72) **Inventors:** BABICH, John, W.; 500 E. 83rd Street, Apt. 10C, New York, New York 10021 (US). WILSON,

Justin; 104 Randolph Road, Ithaca, New York 14850 (US). THIELE, Nikki; 448 Boiceville Road, Brooktondale, New York 14817 (US). KELLY, James; c/o Weill Cornell Medical College, 413 E. 69th Street, New York, New York 10021 (US). PONNALA, Shashikanth; c/o Cornell University, Center for Technology Licensing, 395 Pine Tree Road, Suite 310, Ithaca, New York 14850 (US).

(74) **Agent:** EWING, James, F. et al.; FOLEY & LARDNER LLP, 3000 K Street, N.W., Suite 600, Washington, District of Columbia 20007 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) **Title:** MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN RADIOTHERAPY OF CANCER




FIG. 1A

(57) **Abstract:** The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen ("PSMA") where the compounds are represented by the following Formulas (I), or a pharmaceutically acceptable salt thereof (IA), or a pharmaceutically acceptable salt thereof (II), or a pharmaceutically acceptable salt thereof, wherein M^1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

[Continued on next page]

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))